As expected, the results indicated that tumor size and weight derived from CDC37L1-silenced cells were remarkably smaller and lower in response to sorafenib, while no significant changes were observed between two groups without drug treatment (Fig. 4J, K). This evidence concerns the gene CDC37L1 and neoplasm.